Literature DB >> 10803505

Malignant hematopoietic cell lines: in vitro models for the study of natural killer cell leukemia-lymphoma.

H G Drexler1, Y Matsuo.   

Abstract

Malignancies involving natural killer (NK) cells are rare disorders. The complexity of NK cell-involving disorders has only recently been appreciated. Modern classifications discern immature (precursor) from mature NK cell leukemias-lymphomas. Continuous NK leukemia-lymphoma cell lines represent important model systems to study these neoplasms. While there are a number of putative NK cell lines which are, however, either not characterized, not immortalized, non-malignant, non-NK, or plain false cell lines, six bona fide malignant NK cell lines have been established and are sufficiently well characterized: HANK1, KHYG-1, NK-92, NKL, NK-YS and YT. Except for YT which was derived from a not further defined acute lymphoblastic lymphoma, these cell lines were established from patients with various NK cell malignancies. Five of the six cell lines are constitutively interleukin-2-dependent. Their immunoprofile is remarkably similar: CD1-, CD2+, surface CD3 (but cytoplasmic CD3epsilon+), CD4-, CD5-, CD7+, CD8-, CD16-, CD56+, CD57-, TCRalphabeta-, TCRgammadelta-, negative for B cell and myelomonocytic markers. The immunoglobulin heavy chain and T cell receptor genes are all in germline configuration. All six lines show complex chromosomal alterations, with both numerical and structural aberrations, attesting to their malignant and monoclonal nature. Functionally, these cells which contain azurophilic granules in their cytoplasm are nearly universally positive in NK activity assays. Three of five cell lines are Epstein-Barr virus-positive (type II latency). The composite data on these six cell lines allow for the operational definition of a typical malignant NK cell line profile. NK leukemia-lymphoma cell lines will prove invaluable for studies of normal and malignant NK cell biology.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10803505     DOI: 10.1038/sj.leu.2401778

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  27 in total

1.  Genomic analysis of CD8+ NK/T cell line, 'SRIK-NKL', with array-based CGH (aCGH), SKY/FISH and molecular mapping.

Authors:  Michael R Rossi; Jeff Laduca; John K Cowell; Bejai I S Srivastava; Seiichi Matsui
Journal:  Leuk Res       Date:  2007-07-20       Impact factor: 3.156

2.  CD28-stimulated ERK2 phosphorylation is required for polarization of the microtubule organizing center and granules in YTS NK cells.

Authors:  Xi Chen; David S J Allan; Konrad Krzewski; Baoxue Ge; Hernan Kopcow; Jack L Strominger
Journal:  Proc Natl Acad Sci U S A       Date:  2006-06-26       Impact factor: 11.205

3.  Single Degranulations in NK Cells Can Mediate Target Cell Killing.

Authors:  Lavesh A Gwalani; Jordan S Orange
Journal:  J Immunol       Date:  2018-03-28       Impact factor: 5.422

4.  Genome-wide analyses and functional profiling of human NK cell lines.

Authors:  Justin T Gunesch; Laura S Angelo; Sanjana Mahapatra; Raquel P Deering; Johanna E Kowalko; Patrick Sleiman; John W Tobias; Linda Monaco-Shawver; Jordan S Orange; Emily M Mace
Journal:  Mol Immunol       Date:  2018-07-24       Impact factor: 4.407

Review 5.  Natural killer cell lines in tumor immunotherapy.

Authors:  Min Cheng; Jian Zhang; Wen Jiang; Yongyan Chen; Zhigang Tian
Journal:  Front Med       Date:  2012-03-31       Impact factor: 4.592

6.  JAK3 deregulation by activating mutations confers invasive growth advantage in extranodal nasal-type natural killer cell lymphoma.

Authors:  A Bouchekioua; L Scourzic; O de Wever; Y Zhang; P Cervera; A Aline-Fardin; T Mercher; P Gaulard; R Nyga; D Jeziorowska; L Douay; W Vainchenker; F Louache; C Gespach; E Solary; P Coppo
Journal:  Leukemia       Date:  2013-05-21       Impact factor: 11.528

7.  NKp30 ligation induces rapid activation of the canonical NF-kappaB pathway in NK cells.

Authors:  Rahul Pandey; Christine M DeStephan; Lisa A Madge; Michael J May; Jordan S Orange
Journal:  J Immunol       Date:  2007-12-01       Impact factor: 5.422

8.  STAT3 transcription factor is constitutively activated and is oncogenic in nasal-type NK/T-cell lymphoma.

Authors:  P Coppo; V Gouilleux-Gruart; Y Huang; H Bouhlal; H Bouamar; S Bouchet; C Perrot; V Vieillard; P Dartigues; P Gaulard; F Agbalika; L Douay; K Lassoued; N-C Gorin
Journal:  Leukemia       Date:  2009-05-07       Impact factor: 11.528

9.  Transcription factor expression in cell lines derived from natural killer-cell and natural killer-like T-cell leukemia-lymphoma.

Authors:  Yoshinobu Matsuo; Hans G Drexler; Akira Harashima; Ayumi Okochi; Norio Shimizu; Kunzo Orita
Journal:  Hum Cell       Date:  2004-06       Impact factor: 4.174

10.  Development of GPC3-Specific Chimeric Antigen Receptor-Engineered Natural Killer Cells for the Treatment of Hepatocellular Carcinoma.

Authors:  Min Yu; Hong Luo; Mingliang Fan; Xiuqi Wu; Bizhi Shi; Shengmeng Di; Ying Liu; Zeyan Pan; Hua Jiang; Zonghai Li
Journal:  Mol Ther       Date:  2017-12-19       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.